Two Doses of PRS CK STORM for Severe Viral Pneumonia
Part of Infections, Lungs & breathing clinical trials.
This study tests a new drug called PRS CK STORM to see if it can safely calm the body's overactive immune response (cytokine storm) in people with severe pneumonia from COVID-19, flu, or RSV who need oxygen. It aims to reduce inflammation and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your legal representative must sign a consent form to participate.
- You must be 18 years or older.
- You must have a confirmed pneumonia from COVID-19, influenza A, influenza B, or RSV (positive PCR test within 3 days).
- You must have signs of body-wide inflammation (SIRS), such as fever, fast heart rate, fast breathing, or abnormal white blood cell count.
- You must need oxygen therapy to help you breathe.
- You cannot have a BMI of 35 or higher, serious heart or liver problems, active cancer, or certain infections (HIV, hepatitis B or C).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
This early (Phase 1) study tests AVM0703 in adults who are very sick with lung failure caused by COVID-19 or influenza (flu). It aims to see if the treatment is safe and potentially helpful when standard rescue breathing treatments are not enough.
This trial tests an antiviral drug called Ziresovir in adults with RSV who have health conditions that make them high-risk, such as lung disease, heart disease, or a weakened immune system. It aims to see if the drug can reduce symptoms like coughing and shortness of breath.
This trial tests whether an experimental drug called AP1189, added to standard hospital care, can help people hospitalized with severe breathing problems from viruses like COVID-19, flu, or RSV. The goal is to see if it reduces the need for mechanical ventilation or other life support.
This study tests an experimental drug (STSA-1002) for people with severe breathing problems caused by a viral infection. It aims to see if the drug can help improve oxygen levels and reduce the need for a breathing machine.
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
Hear when a new SARS CoV-2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.